Servier SAS / Cellectis SA

B-cell Acute Lymphoblastic Leukemia and Solid Tumors (allogeneic CAR-T)

7K US cases/yr

Disease Overview

Relapsed/refractory B-cell ALL has dismal outcomes with conventional chemotherapy. Autologous CAR-T cell therapy (later embodied by Kymriah and Yescarta) demonstrated durable remissions but required patient-specific manufacturing — a logistical and economic constraint. Allogeneic 'off-the-shelf' CAR-T from healthy donors aimed to solve manufacturing scale, time-to-treatment, and cost.

Competitive Landscape

In February 2014, when this deal was signed, the CAR-T landscape was almost entirely autologous and pre-approval: Novartis/Penn's CTL019 (later Kymriah, approved 2017), Kite's KTE-C19 (later Yescarta, approved 2017), and Juno's JCAR015/017 were the leading CD19-directed programs. No allogeneic CAR-T had reached the clinic. Cellectis' TALEN gene-editing platform — used to knock out the TCR alpha chain and CD52 to prevent GvHD and enable lymphodepletion — was the most clinically advanced allogeneic approach, with UCART19 the lead asset. Servier paid only $10M upfront plus up to $140M per program in milestones — extraordinarily favorable terms reflecting both Cellectis' weak negotiating position and the field's skepticism that allogeneic CAR-T would work. Servier exercised its UCART19 option in November 2015 after the first compassionate-use cure (the Layla Richards infant ALL case at Great Ormond Street). Servier subsequently partnered with Pfizer for US rights, and the asset migrated to Allogene Therapeutics in 2018 (renamed ALLO-501/501A). Servier terminated the Allogene/Cellectis collaboration in 2022, reflecting the broader struggle of allogeneic CAR-T to match autologous durability.